Sleep Disorders

The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine discussed the daily challenges patients with narcolepsy face.

A proof‐of‐concept assessment showed that women with chronic migraine and insomnia can be reasonably treated with digital cognitive behavioral therapy for insomnia, with data suggesting it may improve both conditions.

The director of the Sleep Clinic at Boston Children’s Hospital discussed the lack of clinical research for pediatric sleep disorders and what the current landscape looks like.

The director of the Sleep Clinic at Boston Children’s Hospital discussed the sleep disorders she sees in her practice, and how she and her colleagues best address these pediatric patients.

Impaired rhythm production and perception in patients with idiopathic REM sleep behavior disorder are correlated with early markers of Parkinson disease, according to study results.

Secondary endpoints and final results from the clinical study will be announced at the end of March 2020.

Following the 2011 guideline development process, this 2020 guideline focused on addressing a number of types of sleep disturbance in children and adolescents with autism spectrum disorder.

New Medicare data has suggested that those with undiagnosed obstructive sleep apnea have higher annual health care costs than their counterparts, with this high economic burden accompanying already impacted function and quality of life.

The drug was previously indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

New data has suggested that although adherence rates for CPAP for patients with OSA are lower than ideal, the benefits patients receive from its use can still be significant.

Using the Sleepio intervention resulted in significantly greater improvement in insomnia symptoms, as well as almost all other outcomes assessed, in women who were pregnant with insomnia.

Neurology News Network for the week ending January 27, 2020.

The novel oxybate agent has been submitted as an investigational treatment for cataplexy and excessive daytime sleepiness in those ages 7 years and older with narcolepsy.

The drug proved effective in extending total sleep time over a 4-week study period, with minimal adverse events observed.

Neurology News Network for the week ending January 11, 2020.

The drug was associated with significant improvements in sleep onset, sleep efficiency, and wake-after-sleep onset for both doses compared with placebo.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Karl Doghramji, MD, medical director of the Jefferson Sleep Disorders Center, reviews optimal management strategies for elderly patients with insomnia disorder.

The small-molecule dual orexin receptor antagonist was approved based on data from 2 pivotal phase 3 studies which showed statistical superiority over placebo for sleep onset latency.

The drug safety warning stems from a review of case reports and clinical studies that showed use of gabapentinoids with or without opioids is associated with serious breathing difficulties.

Nancy Foldvary, DO, MS, director of the Cleveland Clinic Sleep Disorder Center, discussed challenges faced when treating insomnia.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine provided her perspective on the differences in OSA prevalence for men and women and how adherence to CPAP remains a challenge.

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

Krithika Subramanian, PhD discusses the orexin receptor pathway, signals within orexin receptors, and much more surrounding the clinical application of orexin receptor antagonists.